Nearly five years after the Philips Respironics recall reshaped the CPAP market, respondents to a recent HME Newspoll say ...

Breakthrough sleep apnea medication AD109 shows promising results in phase 3 trials, potentially helping 30 million Americans with the condition.

The sleep apnea devices market is primarily driven by the rising prevalence of obstructive sleep apnea (OSA) and related risk factors, as well as by growing public health initiatives, awareness ...